Octreotide and indomethacin in the prevention of post ERCP pancreatitis
- Conditions
- Acute pancreatitis following endoscopic retrograde cholangiopancreatography.Acute pancreatitis, unspecifiedK85.9
- Registration Number
- IRCT20240302061146N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 88
Participants aged between 18 and 75 years
Participants with normal levels of amylase and lipase before undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP).
Presence of high-risk criteria for post-ERCP pancreatitis based on UpToDate recommendations
Multiple cannulations during ERCP
History of previous pancreatitis following ERCP
Dysfunction of type one and two sphincter of Oddi
Repeated injection of contrast material or other fluids into the main pancreatic duct
Balloon dilation of an intact biliary sphincter
Pancreatic sphincterotomy.
Pregnancy or breastfeeding
Known hypersensitivity to somatostatin
Liver or kidney failure
Referral with manifestations of an episode of acute pancreatitis or chronic pancreatitis
Use of antibiotics, antacids, and other medications that may interfere with the effects of somatostatin
History of previous angina, myocardial infarction, or cerebral ischemia within the past three months
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence of post-ERCP pancreatitis. Timepoint: After 5 hours, and after 10 hours following ERCP. Method of measurement: Obtaining a medical history in terms of abdominal pain along with measuring serum levels of amylase and lipase.
- Secondary Outcome Measures
Name Time Method